Breaking News Instant updates and real-time market news.

NTLA

Intellia Therapeutics

$22.71

0.69 (3.13%)

, EDIT

Editas Medicine

$33.59

-0.33 (-0.97%)

12:25
01/08/18
01/08
12:25
01/08/18
12:25

Intellia downplays gene paper amid share decline, STAT reports

Intellia Therapeutics (NTLA) pushed back against an unpublished paper posted Friday on bioRxiv that raised concerns about pre-existing immune responses to CRISPR-based therapies, Andrew Joseph of STAT reports. The company said the issues outlined in the study were either already being addressed or were not relevant to the medicines being developed. Shares of Intellia are down 19% to $18.48 in midday trading while Editas Medicine (EDIT) is down 16% to $28.28 and Crispr Therapeutics (CRSP) is down 5% to $25.45. Reference Link

NTLA

Intellia Therapeutics

$22.71

0.69 (3.13%)

EDIT

Editas Medicine

$33.59

-0.33 (-0.97%)

CRSP

Crispr Therapeutics

$26.81

2.9 (12.13%)

  • 08

    Jan

  • 08

    Jan

  • 26

    Feb

NTLA Intellia Therapeutics
$22.71

0.69 (3.13%)

09/06/17
LEHM
09/06/17
INITIATION
LEHM
Overweight
Intellia Therapeutics initiated with an Overweight at Barclays
Barclays initiated Intellia with an Overweight rating and $29 price target, citing substantial upside as "more clinical data are generated from CRSP/NTLA/EDIT to further support broad application of CRISPR/Cas9 technology."
08/29/17
08/29/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. JA Solar (JASO) downgraded to Sell from Hold at Axiom with analyst Gordon Johnson saying recent results suggest that Chinese module vendors are not benefiting significantly from any U.S. demand pull-in. 2. Finish Line (FINL) was downgraded to Sell from Neutral at Citi and Deutsche Bank, while being downgraded to Underperform from Neutral at Buckingham, and to Neutral from Buy at FBR Capital. 3. Intellia Therapeutics (NTLA) downgraded to Neutral from Buy at Chardan with analyst Madhu Kumar citing relative valuation. 4. Loxo Oncology (LOXO) downgraded to Market Perform from Outperform at JMP Securities with analyst Michael King saying he believes the company's platform and assets under development are now being fairly valued with the stock having risen above his $71 price target. 5. Cemex (CX) downgraded to Neutral from Buy at BofA/Merrill with analyst Carlos Peyrelongue citing lack of positive catalysts and risk of disappointment in Mexico and the U.S. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/31/17
JEFF
10/31/17
NO CHANGE
Target $42
JEFF
Buy
Intellia Therapeutics price target raised to $42 from $36 at Jefferies
10/31/17
LEER
10/31/17
NO CHANGE
Target $37
LEER
Outperform
Intellia Therapeutics price target raised to $37 from $29 at Leerink
Leerink analyst Joseph Schwartz said Intellia Therapeutics' (NTLA) demonstration of gene editing across multiple animal models brings the company one-step closer to an IND filing. He also believes investors are pricing in an M&A premium following Gilead's (GILD) acquisition of Kite and the approvals of Novartis' (NVS) Kymriah and Gilead's Yescarta. Noting that his valuation "now incorporates a very small fraction" of the Kite acquisition value, he raised his price target on Intellia to $37 from $29 and keeps an Outperform rating on the shares.
EDIT Editas Medicine
$33.59

-0.33 (-0.97%)

12/18/17
MSCO
12/18/17
NO CHANGE
MSCO
Morgan Stanley sees opportunities in biotech amid 'limited' investor conviction
With clinical catalysts in large-cap Biotechnology limited to only five key Phase III readouts - three of which are from Alexion (ALXN) - investors are describing their 2018 picks in the space as the "least worst" of the group, according to Morgan Stanley analyst Matthew Harrison. However, he believes this lack of conviction creates real opportunity for outsized moves in 2018, with Amgen (AMGN) identified by Harrison as the biggest potential beneficiary of M&A given "its likely newfound access" to about $39B in offshore cash. Other biotech names the analyst highlights on the up side include Biogen (BIIB), BioMarin (BMRN), Biohaven (BHVN) and Sarepta (SRPT). Meanwhile, Harrison highlights his concerns about potential downside for BioVerativ (BIVV) and Innoviva (INVA), on both of which he keeps Underweight ratings.
07/17/17
OPCO
07/17/17
INITIATION
OPCO
Perform
Crispr Therapeutics initiated with a Perform at Oppenheimer
Oppenheimer analyst Leah Rush Cann started Crispr Therapeutics (CRSP) with a Perform rating saying the company is in a weaker patent position than competitor Editas Medicine (EDIT).
09/06/17
LEHM
09/06/17
INITIATION
LEHM
Overweight
Editas Medicine initiated with an Overweight at Barclays
Barclays initiated Editas Medicine with an Overweight rating and a $28 price target, citing substantial upside as "more clinical data are generated from CRSP/NTLA/EDIT to further support broad application of CRISPR/Cas9 technology."
07/17/17
OPCO
07/17/17
INITIATION
OPCO
Perform
Editas Medicine initiated with a Perform at Oppenheimer
Oppenheimer analyst Leah Rush Cann started Editas Medicine (EDIT) with a Perform rating saying that while the company currently has the strongest patent position among its CRISPR-based peers, the shares are fairly valued.
CRSP Crispr Therapeutics
$26.81

2.9 (12.13%)

09/06/17
LEHM
09/06/17
INITIATION
LEHM
Overweight
Crispr Therapeutics assumed with an Overweight at Barclays
Barclays assumed Crispr with an Overweight rating and a $29 price target, up from $22, citing substantial upside as "more clinical data are generated from CRSP/NTLA/EDIT to further support broad application of CRISPR/Cas9 technology."
12/21/17
PIPR
12/21/17
INITIATION
Target $30
PIPR
Overweight
Crispr Therapeutics assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff assumed coverage of Crispr Therapeutics with an Overweight rating and raised his price target for the shares to $30 from $24. The analyst sees "immense therapeutic potential" for the company's CRISPR/Cas9 gene editing technology.
12/22/17
12/22/17
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Waste Connections (WCN) initiated with a Buy at BofA/Merrill. 2. Carrizo Oil & Gas (CRZO) reinstated with a Neutral at Citi. 3. Crispr Therapeutics (CRSP) assumed with an Overweight at Piper Jaffray. 4. Sierra Bancorp (BSRR) initiated with a Market Perform at Fig Partners. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

ATUS

Altice USA

$21.90

0.6 (2.82%)

, ALLVF

Altice NV

$11.35

0.3675 (3.35%)

04:58
01/23/18
01/23
04:58
01/23/18
04:58
Upgrade
Altice USA, Altice NV rating change  »

Altice USA upgraded to…

ATUS

Altice USA

$21.90

0.6 (2.82%)

ALLVF

Altice NV

$11.35

0.3675 (3.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$227.58

7.12 (3.23%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

ALLVF

Altice NV

$11.35

0.3675 (3.35%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Upgrade
Altice NV rating change  »

Altice NV upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AYR

Aircastle

$24.23

-0.03 (-0.12%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Aircastle management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

CRNCY

Cairn Energy

$6.15

0.11 (1.82%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Cairn Energy management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

SRE

Sempra Energy

$105.05

-0.94 (-0.89%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Sempra Energy management to meet with Wolfe Research »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

TRN

Trinity Industries

$36.51

-0.15 (-0.41%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Trinity Industries management to meet with Wedbush »

Meeting with CFO Perry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

EPE

EP Energy

$2.48

0.17 (7.36%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
EP Energy to hold a conference call »

Management discusses its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Wolfe Research utilities analyst to hold a luncheon meeting »

Senior Utilities Analyst…

RHT

Red Hat

$128.01

2.07 (1.64%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Red Hat participates in a conference call with Bernstein »

U.S. SMID-Cap Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 06

    Feb

CAMP

CalAmp

$23.13

0.02 (0.09%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
CalAmp has a conference call hosted by JPMorgan »

JPMorgan Analyst Coster…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

CQH

Cheniere Energy Partners LP

$28.50

0.28 (0.99%)

, CQP

Cheniere Energy Partners

$30.89

0.41 (1.35%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Morgan Stanley to hold a tour »

Annual Morgan Stanley…

CQH

Cheniere Energy Partners LP

$28.50

0.28 (0.99%)

CQP

Cheniere Energy Partners

$30.89

0.41 (1.35%)

ENLC

EnLink Midstream

$19.25

0.5 (2.67%)

ENLK

EnLink Midstream Partners

$18.08

0.63 (3.61%)

EPD

Enterprise Products

$29.40

0.74 (2.58%)

NBLX

Noble Midstream

$56.22

1.12 (2.03%)

PAA

Plains All American

$23.05

0.56 (2.49%)

SHLX

Shell Midstream

$30.46

0.33 (1.10%)

TRGP

Targa Resources

$51.00

0.27 (0.53%)

WES

Western Gas Partners

$53.74

1.43 (2.73%)

WGP

Western Gas Equity

$41.91

1.49 (3.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 16

    Feb

  • 20

    Feb

  • 26

    Feb

BPL

Buckeye Partners

$55.97

0.95 (1.73%)

, CEQP

Crestwood Equity

$28.50

0.75 (2.70%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
UBS to hold a tour »

Houston Winter MLP &…

BPL

Buckeye Partners

$55.97

0.95 (1.73%)

CEQP

Crestwood Equity

$28.50

0.75 (2.70%)

ENLC

EnLink Midstream

$19.25

0.5 (2.67%)

ENLK

EnLink Midstream Partners

$18.08

0.63 (3.61%)

EPD

Enterprise Products

$29.40

0.74 (2.58%)

PAA

Plains All American

$23.05

0.56 (2.49%)

SEP

Spectra Energy Partners

$43.40

0.81 (1.90%)

SHLX

Shell Midstream

$30.46

0.33 (1.10%)

TRGP

Targa Resources

$51.00

0.27 (0.53%)

WES

Western Gas Partners

$53.74

1.43 (2.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 09

    Feb

  • 16

    Feb

  • 20

    Feb

  • 26

    Feb

SIG

Signet Jewelers

$55.87

0.8 (1.45%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Signet Jewelers management to meet with Buckingham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

FCPT

Four Corners Property Trust

$24.13

0.45 (1.90%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Four Corners Property Trust management to meet with JMP Securities »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

PRQR

ProQR Therapeutics

$3.03

0.025 (0.83%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
ProQR Therapeutics to h old an investor event »

Investor Event will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 19

    Feb

BRG

Bluerock Residential

$9.22

0.03 (0.33%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Bluerock Residential management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

UNF

UniFirst

$171.15

0.2 (0.12%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
UniFirst management to meet with Northcoast »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

ABEO

Abeona Therapeutics

$14.85

0.25 (1.71%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Abeona Therapeutics management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

STML

Stemline

$14.25

0.7 (5.17%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Stemline participates in a conference call with JPMorgan »

Investor conference call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

SBOW

SilverBow Resources

$31.45

-0.79 (-2.45%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
SilverBow Resources management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

BNED

Barnes & Noble Education

$7.71

0.01 (0.13%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Barnes & Noble Education management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

04:55
01/23/18
01/23
04:55
01/23/18
04:55
General news
Breaking General news story  »

Week of 1/19 Redbook to…

IWSY

ImageWare

$2.20

0.12 (5.77%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
ImageWare management to meet with Northland »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

WGO

Winnebago

$52.95

-0.05 (-0.09%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
Winnebago management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.